ImmuPharma (LON:IMM) Shares Up 9.3% – Still a Buy?

ImmuPharma plc (LON:IMMGet Free Report)’s stock price rose 9.3% during trading on Saturday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.94 ($0.05). Approximately 31,560,066 shares changed hands during trading, an increase of 60% from the average daily volume of 19,683,289 shares. The stock had previously closed at GBX 3.60 ($0.04).

ImmuPharma Trading Up 9.3 %

The company has a market capitalization of £16.39 million, a P/E ratio of -393.60 and a beta of 1.53. The business’s 50-day simple moving average is GBX 1.75 and its 200 day simple moving average is GBX 1.73.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.